USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: OPHIDIAN PHARMACEUTICALS, INC.
Address: 5445 East Cheryl Parkway
Madison, WI 53711
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $343,166.00 5
SBIR Phase II $1,240,311.00 2

Award List:

PRODUCTION AND CHARACTERIZATION OF AN AVIAN RICIN ANTITOXIN

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Doug Stafford , Principal Investigator
Award Amount: $49,916.00

PRODUCTION AND CHARACTERIZATION OF AN AVIAN RICIN ANTITOXIN

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency / Branch: DOD / ARMY
Principal Investigator: Doug Stafford , Principal Investigator
Award Amount: $496,410.00
Abstract:
Ophidian pharmaceuticals proposes to test the feasibility of adapting its technology for producing and purifying therapeutic antibodies from the egg yolks of hyperimmunized laying hens to the development of ricin antitoxin. this technology is well suited to the rapid development of… More

Development Africanized Honey Bee Antivenom

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas C. Stafford
Award Amount: $49,617.00
Abstract:
The northward migration from Brazil of the Africanized honey bee (AHB), Apis mellifera scutellata, following their accidental release presents a new U. S. public health concern. Because of the AHB's extremely defensive colony behavior, persons may be attacked by swarms; this will result in hundreds… More

Passive Immune Therapy for Helicobacter Pylori Incection

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Christopher Clemens
Award Amount: $71,192.00
Abstract:
Helicobacter pylori is a gastrointestinal pathogen that causes, or is a major risk factor for thedevelopment of a spectrum of diseases including chronic gastritis, peptic ulcer, and cancer of thestomach. Current therapies for these diseases are inadequate as they are plagued with high… More

Development of an Antidote for E Coli 0157--H7 Verotoxin

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nisha Padhye
Award Amount: $72,496.00

Development of an Antidote for E Coli 0157--H7 Verotoxin

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: Nisha Padhye
Award Amount: $743,901.00
Abstract:
E. coli Ol57:H7 is an emerging food-borne pathogen with substantial morbidity and mortality.There are an estimated 20,000 cases of E. coli 0157:H7 infection per year in the United States.However, only 11 states require reporting of the cases to the State Health Department; hence, the actualnumber of… More

Quantitative Detection of Toxins Using Novel Compounds that Bind to Carbonhydrate Binding Sites

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Dr. Joseph R. Firca
Award Amount: $99,945.00
Abstract:
A novel set of compounds has been devised and synthesized, members of which bind to bacterial toxins with high affinity and selectivity. The compounds are covalently attached to a solid phase and can be used to selectively bind to toxins from various sources (e.g., body fluids or food extracts) for… More